Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Paychex, Inc. (PAYX) vs Vir Biotechnology Inc. Common Stock (VIR) Price & Performance

Paychex, Inc.Trade
Vir Biotechnology Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

Paychex, Inc. vs Vir Biotechnology Inc. Common Stock — how do they compare? Paychex, Inc. trades at $109.38 (market cap $37.82B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: Paychex, Inc. is far larger — about 21× Vir Biotechnology Inc. Common Stock's market cap, and Paychex, Inc. pays a 4.48% dividend while Vir Biotechnology Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Paychex, Inc. for 56 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.

PAYXVIR
Market Cap
$37.82B$1.80B
Volume
2,018,2381,782,836
Sector
IndustrialsHealth
52-Week High
$127.54$11.78
52-Week Low
$85.57$5.12
Typical Hold Time
56 Days0 Days
Enterprise Value
$41.51B$1.36B
Dividend Yield
4.48%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Paychex, Inc.

Paychex (PAYX) trades at $106.26, up 1.55% today, with a bullish technical signal despite some bearish moving average indicators. The company reported a beat on Q2 2026 EPS of $1.34 versus $1.32 expected, continuing a trend of earnings outperformance. Revenue grew to $5.57B in 2025, with strong profitability margins including a 27.35% net income margin and 47.06% ROE. Recent news highlights dividend sustainability concerns amid a stock price decline, though the company maintains a solid financial position.

The outlook for PAYX is mixed; fundamentals remain robust with consistent earnings beats and high profitability, but investor sentiment is cautious due to valuation concerns and labor market exposure. Near-term price action hinges on Q3 2026 earnings and dividend coverage metrics. Risks include economic sensitivity and competitive pressures, while analyst consensus suggests modest upside to a $111 price target.

Vir Biotechnology Inc. Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

PAYX
1% Buy99% Sell
Avg holding period · 56 Days
VIR
51% Buy49% Sell
Avg holding period · 0 Days

About Paychex, Inc.

Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.

Read more on PAYX →

About Vir Biotechnology Inc. Common Stock

Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.

Read more on VIR →